

# Aarti Asnani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9559590/publications.pdf>

Version: 2024-02-01

32  
papers

921  
citations

643344

15  
h-index

536525

29  
g-index

33  
all docs

33  
docs citations

33  
times ranked

1461  
citing authors

#	ARTICLE	IF	CITATIONS
1	Excess heme upregulates heme oxygenase 1 and promotes cardiac ferroptosis in mice with sickle cell disease. <i>Blood</i> , 2022, 139, 936-941.	0.6	68
2	Genetics of Anthracycline-Associated Cardiotoxicity. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 867873.	1.1	9
3	Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 315-330.	0.7	7
4	Understanding Myocardial Metabolism in the Context of Cardio-Oncology. <i>Heart Failure Clinics</i> , 2022, 18, 415-424.	1.0	1
5	Zebrafish Models of Cancer Therapy-Induced Cardiovascular Toxicity. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 8.	0.8	5
6	5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death. <i>Current Cardiology Reports</i> , 2021, 23, 17.	1.3	32
7	Gender Differences in Medicare Payments Among Cardiologists. <i>JAMA Cardiology</i> , 2021, 6, 1432.	3.0	6
8	Activating Autophagy to Prevent Doxorubicin Cardiomyopathy: The Timing Matters. <i>Circulation Research</i> , 2021, 129, 801-803.	2.0	9
9	Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. <i>Circulation</i> , 2021, 144, 1521-1523.	1.6	44
10	Changes in Citric Acid Cycle and Nucleoside Metabolism Are Associated with Anthracycline Cardiotoxicity in Patients with Breast Cancer. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 349-356.	1.1	29
11	Gender differences in industry payments among cardiologists. <i>American Heart Journal</i> , 2020, 223, 123-131.	1.2	16
12	Doxorubicin Cardiotoxicity: Pathophysiology Updates. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	9
13	Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 315-325.	2.3	44
14	In Reply. <i>Oncologist</i> , 2020, 25, e1255-e1256.	1.9	0
15	A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy. <i>Nature Cancer</i> , 2020, 1, 315-328.	5.7	78
16	Uridine Triacetate for Severe Fluoropyrimidine Cardiotoxicity in a Patient With Thymidylate Synthase Gene Variants. <i>JACC: CardioOncology</i> , 2020, 2, 329-332.	1.7	7
17	Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib. <i>JACC: CardioOncology</i> , 2020, 2, 119-122.	1.7	16
18	Cyp1 Inhibition Prevents Doxorubicin-Induced Cardiomyopathy in a Zebrafish Heart Failure Model. <i>ChemBioChem</i> , 2020, 21, 1905-1910.	1.3	15

#	ARTICLE	IF	CITATIONS
19	Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study. <i>Oncologist</i> , 2020, 25, e606-e609.	1.9	23
20	Outcomes of COVID-19 in Patients With a History of Cancer and Comorbid Cardiovascular Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, , 1-10.	2.3	22
21	Cardioprotection in cancer therapy: novel insights with anthracyclines. <i>Cardiovascular Research</i> , 2019, 115, 915-921.	1.8	21
22	Fluoropyrimidine-Associated Cardiotoxicity. <i>Cardiology Clinics</i> , 2019, 37, 399-405.	0.9	47
23	Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. <i>Current Oncology Reports</i> , 2018, 20, 44.	1.8	53
24	Biomarker Discovery in Cardio-Oncology. <i>Current Cardiology Reports</i> , 2018, 20, 52.	1.3	9
25	Beta-Blockers for Primary Prevention of Anthracycline Cardiotoxicity. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2291-2292.	1.2	4
26	Cardiotoxicities associated with immune checkpoint inhibitors. <i>Current Problems in Cancer</i> , 2018, 42, 422-432.	1.0	42
27	Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity. <i>JCI Insight</i> , 2018, 3, .	2.3	31
28	Management of atrial fibrillation in patients taking targeted cancer therapies. <i>Cardio-Oncology</i> , 2017, 3, 2.	0.8	19
29	CHANGES IN CITRIC ACID METABOLISM ARE ASSOCIATED WITH THE DEVELOPMENT OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN MICE AND IN PATIENTS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 669.	1.2	1
30	Optimizing cardio-oncology programs for cancer patients. <i>Future Oncology</i> , 2015, 11, 2011-2015.	1.1	4
31	The zebrafish as a tool to identify novel therapies for human cardiovascular disease. <i>DMM Disease Models and Mechanisms</i> , 2014, 7, 763-767.	1.2	141
32	Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. <i>Science Translational Medicine</i> , 2014, 6, 266ra170.	5.8	109